• EGOC · OTC
  • DUSS · OTC
  • CGFIA · OTCQB
  • POTG · OTCQB
  • EMXC · OTC
  • TYTN · OTC
  • TDGI · OTC
  • LUXD · OTCQB
  • NYXO · OTCQB
  • LBAS · OTCQB
  • Tagged WNDM

    TVGoods, Inc. Announces Spanish Media Campaign for Wound Management’s CellerateRX(R) (WNDM.QB)

    Posted on September 23, 2011 by Dana Salvo

    CelerateRX

    TVGoods Inc. (“TVGoods”), a direct response marketing company and wholly owned subsidiary of H & H Imports, Inc. (PINKSHEETS: HNHI) (OTCQB: HNHI), has announced the launch of the media campaign for CellerateRX®. CellerateRX® (OTCQB: WNDM) is a revolutionary bovine-based collagen that is designed to heal wounds like no other product on the market.

    TVGoods produced a short form infomercial which was dubbed in Spanish for domestic distribution. The infomercial spot is set to roll out on 50 television properties in 36 states across the U.S. The spot is geared toward the Hispanic consumer market and is aimed to drive retail sales to big box and other national and local retailers.

    TVGoods’ initial agreement to produce an infomercial for CellerateRX® was announced on March 1, 2011. TVGoods has an exclusive relationship with Marketing Media Enterprises, LLC to distribute CellerateRX® via CABAN BROADCASTING, LLC. CABAN BROADCASTING, LLC is a boutique network services firm that focuses on matching networks with carriers and advertisers that want to reach the U.S. markets from around the globe.

    Steve Rogai, CEO of TVGoods, stated, “We believe this is a tremendous opportunity for TVGoods. We are excited to have secured media placement for a product with such a promising future in the large Spanish market.”

    Carlos Caban, CEO and President of CABAN BROADCASTING LLC, an exclusive partner of Marketing Media Enterprises, LLC, stated, “We are happy working on this project with MME, LLC and TVGoods. Our television networks in the U.S.A. are ready for the relationship.”

    Laura Hayes-Reeves, President of Marketing Media Enterprises, LLC, stated, “We are delighted and look forward to success with what I believe is a game changing product. We stand poised to expand the relationship with Caban Broadcasting and the Spanish market.”

    About The Company:
    H & H Imports, Inc. is the parent company of TV Goods, Inc. TV Goods, Inc. is a direct response marketing company. We identify, develop and market consumer products for global distribution. TV Goods was established by Kevin Harrington, a pioneer of direct response television. For more information, go to www.TVGoodsInc.com.

    TheStockWizards.net Weekly Newsletter Reviews SAVW, SNGX, MNAP, OPMG, and LBSR as Stocks of Interest

    Posted on July 9, 2011 by Dana Salvo

    SavWatt USA, Inc. (SAVW.OTCBB)

    July 9, 2011 West Palm Beach.FL–TheStockwizards.net penny stock trading system analyzes the most notable explosive OTC, OTCBB, NASDAQ Micro Cap Penny Stocks such as SAVW with huge volume and positive change.

    The TSW Weekly Top 10 watch list looks for OTC small cap penny stocks that have some kind of technical analysis set up in the charts like SAVW. TSW looks for moving average breakouts, chart pattern breakouts, bottom reversals, volume accumulation and more.

    OTC Small-Cap Penny Stocks showing potential momentum, volume accumulation for the coming week include SAVW, SNGX, MNAP, PCFG, OPMG, LBSR, KNKT, EGOH, ADHC and WNDM.

    1-SavWatt USA, Inc. (SAVW.OTCQB) -.0039

    SAVW is getting ready to breakout above its 100-day moving average. A weekly close above this key moving average could set the stock up for an explosive move to the upside. First level of resistance will be the psychological .005 level in the short-term.

    SAVW, SNGX, MNAP, OPMG, LBSR SavWatt is leading the LED lighting revolution and setting the stage to obsolete the incandescent light bulb through the use of energy-efficient, environmentally friendly LED lighting. SavWatt is a market-leading innovator of LED lighting. SavWatt’s product families include LED fixtures, bulbs, Street Lights and Parking Lights. For additional product and company information, please refer to www.savwatt.com. To hear Recorder updates on the company Text SAVW to 46800.

    2- Soligenix, Inc. (SNGX.OTCQB) - .30

    TSW subscribers made a killing in 2009 with the biotech pharmaceutical craze. Could the last six months of 2011 bring us more winners in the biotech pharmaceutical sectors? TSW is adding SNGX to its Biotech watch list.

    Coming out of a nice consolidation pattern SNGX exploded to close the week at a new 52-week high. Strong support .25 first resistance is .38-.40. There could be forward-looking events coming up in the fourth quarter of the year so the stock could possibly continue to move higher from here.

    Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development of products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, as well as biodefense vaccines and therapeutics.

    3- Manas Petroleum Corp. (MNAP.OTCQB) -.40

    Traders and investors felt MNAP was oversold from these levels and bid the stock higher. MNAP had a weekly close above the 50-day moving average. This was an extremely bullish technical event.

    Another weekly close above this key moving average will get the attention of technical traders and could spark another round of momentum buying. With oil closing in on $100 a barrel again, MNAP looks attractive at these levels.

    Manas Petroleum is an international oil and gas company with primary focus on exploration and development in South-Eastern Europe, Central Asia and Mongolia. In Albania, Manas participates in a 1.7 million acre exploration project through its equity interest in Petromanas Energy Inc., a Canadian public company.
    Read the rest of this entry »

    WNDM Files Q1 Results; Company Reports Record Revenue; Cash Position at All-Time High

    Posted on May 18, 2011 by Dana Salvo

    WNDM

    May 18, 2011 — Wound Management Technologies, Inc., (OTCQB: WNDM | WNDM.PK) a leader in advanced wound care solutions, announced financial results for its first quarter of 2011. For the three-month period ending March 31, 2011, revenue was $935,412, a 1,303% increase over first quarter 2010 net revenue of $66,960. The increase in revenue was primarily attributable to enhanced sales efforts in 2010, which continued into the first quarter of 2011. The Company had a loss of $2,743,921 for the first quarter of 2011, as compared to a loss of $1,244,507 for the first quarter of 2010. The loss in the first quarter of 2011 included a non-cash loss of $1,950,882 related to the conversion of certain debt of the Company into equity. Cash flow from operations at 3/31/11 was positive for the first time in the Company’s history, $124,278 as compared to a negative cash flow from operations of $284,810 at 3/31/10.

    Key Financial Comparisons between Q1 2011 & Q1 2010:

    Gross profit rose 1717% to $840,994 versus $46,293.
    Current assets rose 169% to $2,288,521 versus $850,092.
    Current liabilities dropped 29% to $2,468,869 versus $3,479,189.
    Weighted-average number of common shares rose 37% to 46,423,395 from 33,948,681
    Stockholders’ equity rose 87% to $5,377,356.
    Cash on hand as of March 31, 2011, was $1,021,507 versus cash of $50,835 in the prior comparable period.

    Scott Haire, Wound Management Technologies CEO, commented, ” We are very pleased with our first quarter results as well as with the Company’s outlook. During the first quarter, Wound Management achieved several key milestones: a record high in quarterly revenues equal to roughly all of the Company’s 2010 revenues, a significantly improved balance sheet, our first positive cash flow from operations, and the completion of financing that left the company with more than $1M in cash.”

    “The Company is executing extremely well. We expect revenues to continue to increase throughout the remainder of 2011 driven primarily by sales from our existing distributors as well as the opening of new markets for CellerateRx® worldwide.”

    Deborah Jenkins Hutchinson, President of Wound Management Technologies, stated, “We have met the initial goals of our 2011 business plan. The Company has reached milestone revenue targets, rolled out direct-to-consumer sales, and closed an agreement with a major channel partner in Juventus. In Q2, the Company should continue to execute on the business initiatives stated in the Letter to the Shareholders dated April 20, 2011. Some of the progress investors can anticipate includes increasing sales, an agreement for CellerateRx® to go on formulary at a major healthcare system, and entry into the government healthcare market.”

    WNDM Signs $1.5 Million Multiyear Regional Distribution Agreement

    Posted on April 12, 2011 by Dana Salvo

    WNDM

    April 12, 2011 - Wound Management Technologies, Inc., (OTCQB: WNDM) a leader in advanced wound care solutions, today announced that the Company has signed a multi-year agreement with Omni Medical Products of McAllen, Texas to distribute CellerateRX® gel products in select states in the southwestern U.S.  To maintain the distributorship, the agreement calls for 1st year sales of at least $650,000 and additional sales each subsequent year.

    According to Deborah Jenkins Hutchinson, President of Wound Management Technologies, “We are pleased to have Omni Medical Products distributing Wound Management’s gel products in select states.  This agreement is part of our broader campaign to establish CellerateRX® as the standard of care in wound treatment.”

    Ron Mathis, Senior VP of Sales stated, “I am optimistic that as our sales increase we will continue to find broad distribution channels for the product. This new relationship along with our recent television campaigns should help to provide the exposure necessary to grow the company.”

    Scott Haire, WNDM CEO was quoted, “It is exciting to watch as our revenues continue to grow, partnerships like this with Omni along with the recent announcement of our Middle East orders are all very encouraging signs that we will achieve meeting our 2011 revenue projections.”

    For additional news and information concerning the CellerateRX® line of wound care products, please visit Wound Management Technology’s newly re-launched product website www.CellerateRX.com.

    About Wound Management Technologies, Inc.

    Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management’s primary focus is the distribution of its unique, patented collagen product, CellerateRX®, which is FDA cleared and reimbursable under Medicare Part B. Wound Management has other advanced biotech products in development including a patented resorbable bone wax line that is in late stages of development, as well as a subsidiary focused on technology for secure healthcare data collaboration and storage.  More information can be found on the company’s web sites: http://www.wmgtech.com and http://www.celleraterx.com.

    WNDM Secures Additional International Sales; $150 K in New Orders for 2011

    Posted on April 7, 2011 by Dana Salvo

    WNDMFORT WORTH, Texas, April 7, 2011 — Wound Management Technologies, Inc., (OTCBB:WNDM) a leader in advanced wound care solutions, today announced that its Pharma Tech International Joint Venture, which sells wound care products within key international markets, has received new orders for the Company’s line of CellerateRX® powder and gel products.  In Lebanon, the subsidiary just completed a $50,000 order for powder and gel with a second $100,000 order scheduled for shipment later this Month with expectations to ramp up to larger orders by 3rd quarter.

    According to Deborah Jenkins Hutchinson, President of Wound Management Technologies, “I am very excited by these orders and the prospect for further growth in overseas sales.  We believe that the international market represents a significant opportunity for our products due, in part, to the region’s high rate of diabetes and its associated complications.”

    For additional news and information concerning the CellerateRx® line of wound care products, please visit Wound Management Technology’s newly relaunched product website www.CellerateRX.com.

    About Wound Management Technologies, Inc.

    Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management’s primary focus is the distribution of its unique, patented collagen product, CellerateRX®, which is FDA cleared and reimbursable under Medicare Part B. Wound Management has other advanced biotech products in development including a patented resorbable bone wax line that is in late stages of development, as well as a subsidiary focused on technology for secure healthcare data collaboration and storage.  More information can be found on the company’s web sites: http://www.wmgtech.com and http://www.celleraterx.com.

    Foam and Coatings Manufacturer LaPolla Industries (LPAD.OB) leads this weeks Top 10 List along with FCCN, JADA, and NHPR

    Posted on March 13, 2011 by Dana Salvo

    LPAD

    March 13th, 2011 Boca Raton, FL–TheStockwizards.net penny stock trading system analyzes the most notable explosive OTC, OTCBB, and NASDAQ Micro Cap Penny Stocks such as LPAD with huge volume and positive change.

    The TSW Weekly Top 10 watch list looks for OTC small cap penny stocks that have some kind of technical analysis set up in the charts. TSW looks for moving average breakouts, chart pattern breakouts, bottom reversals, volume accumulation and more.

    OTC Small-Cap Penny Stocks showing potential momentum, volume accumulation for the coming week include: LPAD, FCCN, WELL, JADA, IWEB, ALZM, WNDM, NHPR, DSKX, and TMSH.

    1) Lapolla Industries (LPAD) – 0.57

    Lapolla Industries, Inc. is a manufacturer of spray foam insulation and cool roof coating products targeting commercial, industrial and residential applications in the roofing and insulation construction industries. Additional information about Lapolla is available at www.Lapolla.com.

    2) Spectral Capital Corp. (FCCN) – 1.63

    Spectral Capital is focused on the acquisition of a significant portfolio of properties for mining activities. In September 2010, the Company purchased an interest in mineral properties in the Chita region of the Russian Federation. The Kadara and Kaltagay license is located in the Mogochinsky district of the Chita Region, which has several gold mines in production, in the Russian Federation. Spectral owns 52% of the License for prospecting, exploration and production of gold and all other metals.

    3) Capsalus Corp. (WELL) – 0.04

    Capsalus Corp. is a public company that partners with and acquires visionary enterprises producing progressive, broad-based solutions in the health and wellness space for better physical, nutritional and emotional health worldwide. Capsalus, which derives its name from “Salus,” the Roman goddess of health and prosperity, provides companies in varying stages of development with the operating infrastructure, strategic pathways and financial support to get them to the mass market quickly and efficiently. Read the rest of this entry »

    Wound Management’s (OTCBB: WNDM) Patented CelerateRX Used To Treat Diabetic Wounds

    Posted on March 7, 2011 by Dana Salvo

    (OTCBB: WNDM) Patented CelerateRX Used To Treat Diabetic Wounds


    Alternative Energy Company Universal Bioenergy (UBRG) leads this weeks Top 10 List along with SFNL, BLUG, and EERG

    Posted on March 5, 2011 by Dana Salvo

    TheStockWizards.net

    March 05th, 2011 Boca Raton, FL–TheStockwizards.net penny stock trading system analyzes the most notable explosive OTC, OTCBB, and NASDAQ Micro Cap Penny Stocks such as UBRG with huge volume and positive change.

    The TSW Weekly Top 10 watch list looks for OTC small cap penny stocks that have some kind of technical analysis set up in the charts. TSW looks for moving average breakouts, chart pattern breakouts, bottom reversals, volume accumulation and more.

    OTC Small-Cap Penny Stocks showing potential momentum, volume accumulation for the coming week include: UBRG, SFNL, RCMH, BLUG, GLEC, LWSP, WNDM, CMSI, DSKX, and EERG.

    1) Universal Bioenergy Inc. (UBRG.PK) – 0.05

    Universal Bioenergy Inc. is an alternative energy company that markets natural gas and green alternative energy, and is expanding into solar, biofuels, wind, synthetic fuels and related clean energy technology products. It plans to build the company into a prominent player in alternative energy.

    2) Secured Financial NW (SFNL.OB) – 0.066

    RedFin Network is a payment solutions provider, operating a powerful Payment Gateway used to perform Secure Electronic Payment Processing. RedFin Network specializes in providing reliable and robust solutions to eCommerce and Mobile Commerce, offering a comprehensive yet simple suite of Products and Services. The RedFin Network Payment Gateway is CISP (Cardholder Information Security Program) and PCI (Processor Card Industry) compliant. RedFin Network is a wholly owned subsidiary of Secured Financial Network, Inc.

    3) Reach Messaging Holdings, Inc. (RCMH.OB) – 0.024

    Reach Messaging Holdings Inc. helps companies extend their brands through customized mobile Apps and Bots used on mobile and instant messaging (IM) platforms. Since 2007, Reach Messaging has been in the Bot development business for America Online (AOL), which operates on AOL Instant Messenger (AOLIM). The Company has transitioned to the mobile Apps market and is currently developing a variety of Apps and App related technology for social media platforms including Facebook and all of the major mobile devices such as the iPhone, BlackBerry, Android and Digital Signage. Read the rest of this entry »

    Special Biotech Report on Wound Management Technologies (OTCBB:WNDM)

    Posted on March 2, 2011 by Dana Salvo

    The Stock Wizards Featured Profile

    TV Website for CellerateRX (Brought to you by TV Goods)

    WNDM

    Wound Management Technologies, Inc

    Current Price - 0.615 Cents

    www.WmgTech.com WNDM

    Wound Management Technologies, Inc. (WNDM) is a rapidly growing provider of advanced biotechnology products. The company’s unique, patented CellerateRX® products address the very large and growing advanced wound care markets. The U.S. market in 2007 was $3.0B and is projected to double by 2013 (source BCC research).

    With an amazing product like CellerateRX® and a market cap of only approx. 23 million, The Stock Wizards is very surprised to see WNDM trading down at these levels.

    Here is a list of some very impressive features of CellerateRX®:

    *No prescription required.

    *Reduces pain.

    *Cost effective.

    *Reimbursed by Medicare in most States.

    *Cleared by the FDA as a medical device for use on all acute and chronic wounds except for 3rd degree burns.

    *Available in powder and gel.

    *Biocompatible, biodegradable.

    *Easy to use - prepare the wound bed, apply product, cover it up.

    *Used to treat diabetic wounds. The diabetic and long term care markets are a major focus due to the prevalence of diabetic and pressure ulcers.

    “The clinical results we have observed have validated the science beyond the product. I would highly recommend CellerateRX® to any conscientious wound care provider”Desmond P Bell, Jr. DPM, President & Co-Founder, Save a Leg, Safe a Life Foundation.

    Core Revenue Stream: Wound Care Innovations, LLC (WCI)
    Wound Care Innovations is a wholly owned subsidiary of WNDM and brings a unique and dynamic mix of expertise, products, procedures and service to the wound care arena. WCI was formed with the sole purpose of bringing CellerateRX® and activated collagen-based products to the $3B US wound care market. Since then, WCI has expanded marketing internationally.

    Evidence-based Clinical Studies
    CellerateRX® has current and on-going evidenced-based studies and other clinical peer reviewed publications. These can be found on the CellerateRX website.

    Sales & Marketing Channel Expansion
    Having completed evidence-based studies, the company developed its sales channel plan and engaged sales & marketing executives in April 2010.

    Strategic Biotechnology Acquisitions, Products
    In the fall of 2009 WMND acquired a patent for resorbable bone wax and bone void filler products in a subsidiary: Resorbable Orthopedic Products, LLC. The worldwide bio materials market for these types of products is over $1.4 Billion. WNDM anticipates our new products will be cleared by the FDA and ready for marketing in the 1H 2011.

    eHealth Technology Acquisition
    In February 2010, WNDM acquired secure data and messaging provider Secure eHealth, LLC. Secure eHealth has a complete suite of scalable products for secure intelligent healthcare communication, collaboration, storage and transport.

    WNDM
    Market Cap: approx. $23.15M (03/01/11)
    Recent Price: $0.615 (03/01/11)
    Shares Outstanding: 37,661,225 (3Q 2010)
    Estimated Float: 3.3M
    Fiscal Year: December 31

    2011 Projections
    Revenue: $6 M
    Net Income: $1.4 M

    StockBlaster.com

    Discloser, Disclaimers: http://thestockwizards.net/about/disclaimer/

    Read the rest of this entry »

    Wound Care Company (WNDM) offering CelerateRX leads this Weeks Top 10 List along with BLTA, BULM, and DSKX

    Posted on February 28, 2011 by Dana Salvo

    WNDM

    February 27th, 2011 Boca Raton, FL–TheStockwizards.net penny stock trading system analyzes the most notable explosive OTC, OTCBB, and NASDAQ Micro Cap Penny Stocks such as WNDM with huge volume and positive change.

    The TSW Weekly Top 10 watch list looks for OTC small cap penny stocks that have some kind of technical analysis set up in the charts. TSW looks for moving average breakouts, chart pattern breakouts, bottom reversals, volume accumulation and more.

    OTC Small-Cap Penny Stocks showing potential momentum, volume accumulation for the coming week include: WNDM, BLTA, LQMT, SXLP, DIET, BCLI, BULM, GLER, DSKX and FLPC.

    1) Wound Management Tech (WNDM.OTCQB) - 0.58

    Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. It is estimated that aging populations and the increase of the number of patients diagnosed with diabetes will fuel additional rapid growth of this market. Wound Management’s primary focus is the distribution of its unique, patented collagen product, CellerateRX®, which is FDA cleared and reimbursable under Medicare Part B. It has proved to be both clinically effective and cost effective with broad uses over a wide spectrum of wounds. I More information can be found on the company’s web sites: http://www.wmgtech.com and http://www.celleraterx.com.

    2) Baltia Air Lines Inc. (BLTA.QB) – 0.045

    Baltia Air Lines, Inc. is a New York corporation with base of operations in Terminal 4 at JFK International Airport in New York. Today, after JetBlue and Virgin America, Baltia Air Lines is the only new start-up United States Part 121 (heavy jet operator) airline in existence that has received Department of Transportation approval. Baltia’s goal is to become the leading U.S. airline in the trans-Atlantic market between the major U.S. cities and capital cities of Eastern Europe, including Russia, Latvia, Ukraine, and Belarus. Baltia intends to provide high quality three-class passenger service, and reliable cargo and mail transportation. Baltia plans to begin their scheduled air transportation as the only U.S. airline, connecting directly, to two of the world’s most prominent cities — New York and St. Petersburg.
    For more information on Baltia visit the company web site at: www.Baltia.com. Read the rest of this entry »